Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: Sunitinib and sorafenib

Anti-Cancer Drugs

Volumn 21, Issue 2, 2010, Pages 206-209

  Chung, Caroline ^a   Dawson, Laura A ^a   Joshua, Anthony M ^a   Brade, Anthony M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Dermatitis; Radiation recall; Sorafenib; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

SORAFENIB; STEROID; SUNITINIB;

ADULT; ARTICLE; BONE LESION; BONE METASTASIS; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PRIORITY JOURNAL; PRURITUS; RADIATION DERMATITIS; RADIATION DOSE; RADIATION RECALL DERMATITIS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HUMANS; INDOLES; KIDNEY NEOPLASMS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; RADIODERMATITIS; TREATMENT OUTCOME;

EID: 76149123563     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328333d679     Document Type: Article

References (13)

1. Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 2001; 59:237-245.
2. Hymes SR, Strom EA, Fife C. Radiation dermatitis: Clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol 2006; 54:28-46.
3. Ristic B. Radiation recall dermatitis. Int J Dermatol 2004; 43:627-631.
4. Law AB, Junor EJ. Chemotherapy-induced recall of cetuximab and radiation skin reaction. Clin Oncol (R Coll Radiol) 2009; 21:77-78.
5. Chung C, Stuart D, Keyes M. Radiation recall reaction induced by adjuvant trastuzumab (herceptin). Case Report Med 2009; 2009:307-894.
6. Shrimali RK, McPhail NJ, Correa PD, Fraser J, Rizwanullah M. Trastuzumabinduced radiation recall dermatitis - first reported case. Clin Oncol (R Coll Radiol) 2009; 21:634-635.
7. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24:25-35.
8. Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008; 158:592-596.
9. Hsieh CH, Jeng KS, Lin CC, Chen CK, Liu CY, Lin CP, et al. Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. Clin Drug Investig 2009; 29:65-71.
10. Smith KJ, Germain M, Skelton H. Histopathologic features seen with radiation recall or enhancement eruptions. J Cutan Med Surg 2002; 6:535-540.
11. Tan CT, Dargeon HW, Burchenal JH. The effect of actinomycin D on cancer in childhood. Pediatrics 1959; 24:544-561.
12. Azria D, Magne N, Zouhair A, Castadot P, Culine S, Ychou M, et al. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 2005; 31:555-570.
13. Phillips KA, Urch M, Bishop JF. Radiation-recall dermatitis in a patient treated with paclitaxel. J Clin Oncol 1995; 13:305.